Optimizing Protection for NSTE-ACS Patients with Antiplatelet Therapy

Share:
Credit Area      

Release Date: Jan 27, 2010          Expiration Date: Jan 27, 2011



This program has an associated Grand Rounds Click Here for information.

Program Description


Despite advances in acute and chronic treatment of acute coronary syndrome (ACS) patients, there is still considerable uncertainty among physicians about the relative benefits of various antiplatelet agents in protecting against long-term ischemic complications. Interventional cardiologists, general cardiologists, hospitalists, and the entire cath-lab staff have expressed a need for additional education on these issues. Education will clarify the subtle differences between available and emerging agents for preventing thrombotic events, including their relative risks for bleeding complications. As a result, the gap between physician knowledge of antiplatelet agents and the application of that knowledge in practice can be reduced, and the long-term management of ACS patients improved.

This program will also explore the limitations of current antiplatelet therapies and how they might be best managed. In addition, participants will be alerted to the potential importance of emerging therapies that can transform the clinical management of these patients.


Program Format


Didactic lectures providing up-to-date information on dual antiplatelet therapy.


Learning Objectives


At the conclusion of this activity, participants should be able to:

  1. Explain the importance of long-term dual platelet inhibition to protect post-ACS and post-PCI patients against thromboembolic events
  2. Describe the strengths and limitations of current antiplatelet treatment options, along with the need to balance reduction of ischemic thromboembolic complications with minimization of excessive bleeding risks
  3. Discuss emerging oral antiplatelet treatments suitable for long-term protection against risks of thromboembolic events
  4. Differentiate patients and therapies to optimize therapeutic management of post-ACS and post-PCI

Target Audience


Interventional cardiologists, ER physicians, and allied health professionals who treat patients with ACS.

Accreditation


The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CME Credit


The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 AMA PRA Category I credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Disclosure Statement


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Sandep Nathan, MD: Speaker:Medtronic, Sanofi-Aventis;Consultant:Medicure, Inc.;Investigator:Medicure, Inc.; Advisory Panel:Sanofi-Aventis.

Deepak L. Bhatt, MD, FACC, FAHA: Investigator:Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, The Medicines Company.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Barry Watkins, PhD; Robert E. Lamb, PharmD; Jay Katz; Brad Pine; Blair St. Amand: Nothing to Disclose.


FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.
By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.


Supported By


This activity is supported by an educational grant from            
Educational Partner